Treatment of chemotherapy-induced emesis in children;Traitement des vomissements induits par la chimiotherapie des cancers chez l'enfant

Archives de Pediatrie

Volumn 5, Issue 6, 1998, Pages 661-668

  Guitteny, M A ^a   Pajot, C ^a   Chalumeau, M ^a   Pein, F ^a   Grill, J ^a   Hartmann, O ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Child; Drug chemotherapy; Neoplasms; Serotonin antagonists; Vomiting

Indexed keywords

ACETYLCHOLINE; ALIZAPRIDE; ALPRAZOLAM; ANTIINFECTIVE AGENT; BENZODIAZEPINE; BUTYROPHENONE DERIVATIVE; CANNABINOID; CHLORPROMAZINE; CORTICOSTEROID; DOPAMINE; HISTAMINE; METHYLPREDNISOLONE SODIUM SUCCINATE; METOCLOPRAMIDE; METOPIMAZINE; MORPHINE; NEUROLEPTIC AGENT; ONDANSETRON; PHENOTHIAZINE DERIVATIVE; SEROTONIN; SEROTONIN ANTAGONIST;

ARTICLE; CHEMOTHERAPY; DRUG INDICATION; HUMAN; TREATMENT PLANNING; VOMITING;

EID: 0032102220     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-693X(98)80175-9     Document Type: Article

References (47)

1. 1 Coates A, Abraham S, Kaye SB et al. On the receiving end -patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983 ; 19 : 203-8
2. 2 Richardson JL, Marks G, Levine A. The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. J Clin Oncol 1988 ; 6 : 1746-52
3. 3 Chalumeau M, Amigo ME, Delgado R, Grill J, Hartmann O. Pneumomediastinum, a rare, impressive but benign complication of chemotherapy-induced emesis in children. Pediatr Hematol Oncol (in press)
4. 4 Osoba D, Zee B, Warr D, Latreille J, Kaizer I, Pater J et al. Effects of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Comittees of the National Cancer Institute of Canada Clinical Trials Group. Support Care Cancer 1997 ; 5 : 307-13
5. 5 Zeltzer LK, LeBaron S, Zeltzer PM et al. A prospective assessment of chemotherapy-related nausea and vomiting in children with cancer. Am J Pediatr Hematol Oncol 1984 ; 6 : 5-16
6. 6 Rhodes VA, Watson PM, Johnson MH. Pattern of nausea, vomiting and distress in patients receiving antineoplastic drug protocols. Oncol Nurs Forum 1987 ; 14 : 35-44
7. 7 Miller AD, Leslie RA. The area postrema and vomiting. Front Neuroendocrinol 1994 ; 15 : 301-20
8. 8 Cubeddu LX. Mechanisms, by which cancer chemotherapeutic drugs induce emesis. Semin Oncol 1992 ; 19 : 2-13
9. 9 Leslie RA. Neuroactive substances in the dorsal vagal complex of the medulla oblongata: nucleus of the tractus solitarius, area postream and dorsal motor nucleus of the vagus. Neurochem Int 1985 ; 7 : 191-211
10. 10 Stafanini E, Clement-Cormier Y. Detection of dopamine receptors in the area postrema. Eur J Pharmacol 1981 ; 74 : 257-60
11. 11 Tyers MB. 5HT3 receptors. Ann N Y Acad Sci 1990 ; 600 : 194-202
12. 12 Du Bois A, Vach W, Wechsel U, Holy R, Schaefer W. 5-Hydroxyindoleacetic acid (5-HIAA) and cortisol excretion as predictors of chemotherapy-induced emesis. Br J Cancer 1996 ; 74 : 1137-40
13. 13 Howthorn J, Cunningham D. Dexamethasone can potentiate the anti-emetic action of a 5HT3 receptor antagonist on cyclophosphamide induced vomiting in the ferret. Br J Cancer 1990 ; 61 : 56-60
14. 14 Domïnguez-Ortega L, Cubedo-Cervera R, Cortes-Funes H, Diaz-Gallego E. Sleep protects against chemotherapy induced emesis. Cancer 1996 ; 77 : 1566-70
15. 15 Gralla RJ. Metoclopramide: a rewiew of antiemetic trials. Drugs 1983 ; 25 : 63-73
16. 2. Eur J Cancer 1996 ; 32A : 1744-8
17. 17 Lemerle J, Amaral D, Southall DP, Upward J Murdoch RD. Efficacy and safety of granisetron in the prevention of chemotherapy-induced emesis in pediatric patients. Eur J Cancer 1991 ; 27: 1081-3
18. 18 Pinkerton CR, Williams D, Wootton C, Meller ST, McElwain TJ. 5HT3 antagonist ondansetron-an effective outpatient antiemetic in cancer treatment. Arch Dis Child 1990 ; 65 : 822-5
19. 19 Hewitt M, McQuade B, Stevens R. The efficacy and safety of ondansetron in the prophylaxis of cancer-chemotherapy induced nausea and vomiting in children. Clin Oncol (R Coll Radiol) 1993 ; 5 : 11-4
20. 20 Jacobson SJ, Shore RW, Greenberg M, Spielberg SP. The efficacy and safety of granisetron in pediatrc cancer patients who had failed standard antiemetic therapy during anticancer chemotherapy. Am J Pediatr Hematol Oncol 1994 ; 16 : 231-5
21. 21 Perez EA, Navari RM, Kaplan HG, Gralla RJ, Grunberg SM, Palmer RH et al. Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis. Support Care Cancer 1997 ; 5 : 31-7
22. 22 Matsukado K, Nakano S, Bartus R, Black K. Steroids decrease uptake of carboplatin in rat gliomas - uptake improved by intracarotid infusion of bradykinin analog, RMP-7. J Neuro-Oncol 1997 ; 34 : 131-8
23. 23 Greenberg DB, Surman OS, Clarke J, Baer L. Alprazolam for phobic nausea and vomiting related to cancer chemotherapy. Cancer Treat Rep 1987 ; 71 : 549-50
24. 24 Triozzi PL, Goldstein D, Laszlo J. Contributions of benzodiazepines to cancer therapy. Cancer Invest 1988 ; 6 : 103-11
25. 25 Hesketh J, Kris G, Grunberg M, Beck T, Hainsworth JD, Harker G et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997 ; 15 : 103-9
26. 26 Jordan NS, Schauer PK, Schauer A, Nightingale C, Golub G, Martin RS et al. The effect of administration rate on cisplatin-induced emesis. J Clin Oncol 1985 ; 3 : 559-61
27. 27 Billett A, Sallan SE. Antiemetics in children receiving cancer chemotherapy. Support Care Cancer 1994 ; 2 : 279-85
28. 28 Olver IN, Simon RM, Aisner J. Antiemetic studies: a methodological discussion. Cancer Treat Rep 1986 ; 70 : 555-63
29. 29 Alvarez O, Freeman A, Bedros A, Call SK, Volsch J, Kalbermatter O et al. Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies. J Pediatr Hematol Oncol 1995 ; 17 : 145-50
30. 30 Roila F, Tonato M, Cognetti F, Cortesi E, Favalli G, Marangolo M et al. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized cossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991 ; 9 : 675-8
31. 31 Herrstedt J, Sigsgaard T, Boesgaard M, Jensen TP, Dombernovsky P. Ondansetron plus metopimazide compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. New Engl J Med 1993 ; 328 : 1076-80
32. 32 Gebbia V, Testa A, Cannata G, Gebbia N. Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study. Anticancer Drugs 1996 ; 7 : 734-7
33. 33 Kris MG, Gralla RJ, Clark RA, Tyson LB, O'Connell JP, Wertheim MS et al. Incidence, course, and severity delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 1985 ; 3 : 1379-84
34. 34 Kris MG, Gralla RJ, Tyson LB, Clarck RA, Cirrincione C, Groshen S. Controlling delayed vomiting: double-blind randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 1989 ; 7 : 108-14
35. 35 The Italian Group for Antiemetic Research. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. J Clin Oncol 1997 ; 15 : 124-30
36. 36 Olver I, Paska W, Depierre A, Seitz JF, Stewart DJ, Goedhals L. A multicentre, double-bund study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group. Ann Oncol 1996 ; 7 : 945-52
37. 37 LeBaron S, Zeltzer LK, LeBaron C, Scott SE, Zeltzer PM. Chemotherapy side effects in pediatric oncology patients: drugs, age and sex as risk factors. Med Pediatr Oncol 1988 ; 16 : 263-8
38. 38 Dolgin MJ, Katz ER, McGinty K, Siegel SE. Anticipatory nausea and vomiting in pediatric cancer patients. Pediatrics 1996 ; 75 : 547-52
39. 39 Andrykowski MA, Redd WH, Hatfield AK. Development of anticipatory nausea: a prospective analysis. J Consult Clin Psychol 1985 ; 53 : 447-54
40. 40 Morrow GR, Lindke J, Black PM. Predicting development of anticipatory nausea in cancer patients: prospective examination of eight clinical characteristics. J Pain Symptom Manage 1991 ; 6 : 215-23
41. 41 Zeltzer L, LeBaron S, Zeltzer PM. The effectiveness of behavioral intervention for reduction of nausea and vomiting in children and adolescents receiving chemotherapy. J Clin Oncol 1984 ; 2 : 683-90
42. 42 Zeltzer LK, Dolgin MJ, LeBaron S, LeBaron C. A randomized, controlled study of behavioral intervention for chemotherapy distress in children with cancer. Pediatrics 1994 ; 8 : 34-42
43. 43 Hawkins PJ, Liossi C, Ewart BW, Smith JG. Hypnotherapy for control of anticipatory nausea and vomiting in children with cancer: preliminary findings. Psychooncology 1995 ; 4 : 101-6
44. 44 Harding RK, Young RW, Anno GH. Radiotherapy-induced emesis. In: Andrews PLR, Sanger GJ, eds. Emesis in Anti-Cancer Therapy: Mechanisms and Treatment. London: Chapman and Hall; 1993. p 163-78
45. 45 Spitzer TR, Bryson JC, Cirenza E, Foelberg R, Wallerstadt M, Stout C et al. Randomized double-blind, placebo-controlled evaluation of oral ondansetron in the prevention of nausea and vomiting associated with fractionated total-body irradiation. J Clin Oncol 1994 ; 12 : 2432-8
46. 46 Zoubek A, Kronberger M, Puchmann A, Gadner H. Ondansetron in the control of chemotherapy-induced and radiotherapy-induced emesis in children with malignancies. Anticancer Drugs 1993 ; 4 : 17-21
47. 47 Lippens RJ, Breeders GC. Ondansetron in radiation therapy of brain tumor in children. Pediatr Hematol Oncol 1996 ; 13 : 247-52